Announcement
14.05.2012
NeuroSearch A/S (NEUR) has received information from UBS AG, Switzerland, that the company has sold its NeuroSearch shares and now holds 0% of the NeuroSearch share capital.
Patrik Dahlen
CEO
Contact person
René Schneider, EVP & CFO, telephone: +45 4460 8700 or +45 2911 2097
About NeuroSearch
NeuroSearch is a European-based biopharmaceutical company specialising in CNS diseases. The company is listed on NASDAQ OMX Copenhagen A/S. The company’s product pipeline comprises Huntexil® for the treatment of motor symptoms in patients with Huntington's disease and ordopidine and seridopidine, which have both completed phase I development. Huntexil® is currently in Phase III development. The overall objective for NeuroSearch is to create a profitable, specialty pharma company building on the platform the company will achieve from a successful development and marketing of Huntexil®. The company also has a portfolio of assets for outlicensing or divestment.
Attachments
Recommended Reading
-
Company announcement no. 24 - 267 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described...
Read More -
Company announcement no. 23 - 2630 June 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...
Read More